A 48-year-old woman from Mumbai presents with a 3-month history of severe diarrhea, weight loss, and abdominal cramping. She has a past medical history of rheumatoid arthritis treated with NSAIDs for 5 years. Endoscopy shows multiple gastric ulcers with a clean base. Serum gastrin is 95 pg/mL (normal <100), and gastric pH is 3.8. Which of the following mechanisms best explains the reduced gastric acid secretion in this patient?

Explanation

## Clinical Presentation: NSAID-Induced Gastric Ulcer with Atrophic Gastritis This patient presents with: - Chronic NSAID use (5 years for rheumatoid arthritis) - Multiple gastric ulcers with clean base (typical of NSAID injury) - **Elevated gastric pH (3.8)** — indicating reduced acid secretion - Normal serum gastrin (95 pg/mL) — ruling out ZES or compensatory hypergastrinemia - Diarrhea and weight loss — suggesting chronic mucosal damage and possible malabsorption ## Pathophysiology of NSAID-Induced Atrophic Gastritis **Key Point:** Chronic NSAID use causes progressive mucosal damage leading to **loss of parietal cell mass** and **atrophic gastritis**, resulting in reduced acid secretion capacity. ### Mechanism of NSAID-Induced Mucosal Injury ```mermaid flowchart TD A[Chronic NSAID use]:::action --> B[Inhibition of COX-1 and COX-2]:::outcome B --> C[Reduced PGE2 and PGI2]:::outcome C --> D[Loss of mucosal cytoprotection]:::outcome D --> E[Direct mucosal damage]:::action E --> F[Chronic inflammation]:::action F --> G[Parietal cell atrophy and loss]:::outcome G --> H[Reduced acid secretion capacity]:::outcome H --> I[Elevated gastric pH]:::outcome ``` ### Histological Changes in Atrophic Gastritis | Stage | Pathology | Acid Secretion | Serum Gastrin | |-------|-----------|----------------|---------------| | **Normal** | Intact fundic glands with parietal cells | Normal | Normal (<100) | | **Chronic gastritis** | Inflammatory infiltrate, intact glands | Normal or ↓ | Normal or ↑ | | **Atrophic gastritis** | Loss of glandular tissue, parietal cell atrophy | ↓↓ | Normal or ↑ | | **Severe atrophy** | Intestinal metaplasia, minimal glands | ↓↓↓ | ↑ (compensatory) | **High-Yield:** In this case, the **normal serum gastrin despite elevated pH** indicates that the stomach still has **some parietal cell function** (enough to produce acid and suppress gastrin via feedback), but the **total acid secretion capacity is reduced** due to parietal cell loss. ## Why Option 1 (Correct Answer) Is the Best Explanation **Clinical Pearl:** The elevated gastric pH (3.8) in the presence of normal serum gastrin is pathognomonic for **parietal cell loss/atrophy**, not for increased somatostatin or other inhibitory mechanisms. 1. **Mechanism:** Chronic NSAID-induced mucosal damage → chronic inflammation → progressive parietal cell atrophy and loss 2. **Result:** Reduced parietal cell mass → reduced maximum acid secretion capacity 3. **Serum gastrin remains normal** because the remaining parietal cells still produce enough acid to maintain normal pH feedback inhibition of G cells 4. **If atrophy were severe,** gastrin would rise (compensatory response to achlorhydria) **Mnemonic: NSAID Mucosal Injury** — **PGE** - **P**rostaglandin E2 (and PGI2) inhibition - **G**astric mucosal cytoprotection lost - **E**rosion and ulceration → chronic inflammation → atrophy ## Differential Diagnosis of Elevated Gastric pH | Cause | Gastric pH | Serum Gastrin | Mechanism | |-------|-----------|---------------|----------| | **Parietal cell atrophy (NSAID, autoimmune)** | >3 | Normal or ↑ | Loss of acid-secreting cells | | **Somatostatin excess** | >3 | Low | D-cell hyperplasia or tumor (rare) | | **Secretin excess** | >3 | Low | S-cell hyperplasia or tumor (very rare) | | **Achlorhydria (severe atrophy)** | >6 | ↑↑ (>1000) | Complete loss of parietal cells | ## Clinical Implications **Key Point:** NSAID-induced atrophic gastritis is a chronic, progressive condition. Management includes: 1. **Discontinue NSAIDs** (switch to acetaminophen or selective COX-2 inhibitors if necessary) 2. **Proton pump inhibitor** for symptom relief and ulcer healing 3. **Monitoring for intestinal metaplasia** and gastric cancer risk (especially if H. pylori co-infection) [cite:Harrison 21e Ch 297; Robbins 10e Ch 17]